Pelvic Cancer Registry for Online Adapted Radiotherapy

Pelvic Tumor Clinical Trial

— PRoART  

Official title:

Pelvic and Thoracic Cancer Treated With Online Adapted Radiotherapy: A Prospective Registry-based Phase-II Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06185062
• Other study ID #: 2023-02727
• Status: Recruiting
• Start date: January 1, 2024
• Est. completion date: April 2030

Study information

• Verified date: February 2024
• Source: University Medical Center Goettingen
• Contact: Laura Anna Fischer
• Phone: +49 551 3964501
• Email: laura-anna.fischer[@]med.uni-goettingen.de
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This prospective registry-based trial will include patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART or IGRT. For the primary endpoint and the secondary clinical endpoints, the trial will compare oART versus IGRT, for technical endpoints the trial will compare the real oART scenario with two virtual (hypothetical) control scenarios.

Primary endpoint:

• 10% reduction in the rate of acute radiotherapy related toxicity (≥ CTCAE II°, v5.0) using oART

Secondary endpoints:

• Clinical endpoints: Tumor control, late toxicities compared to conventional irradiated patients, quality of life and patient-reported outcomes

• Technical endpoints: Target volume, target coverage, dose to organs at risk, anatomical variability score

Description:

Background: Conventional Radiotherapy (Image Guided Radiotherapy, IGRT) requires a CT-based treatment planning process a priori. During this process, a treatment plan is calculated, which then is applied to the patient with a linear accelerator on a daily basis, possibly using image guidance to account for variability in patient position. However, daily changes of the anatomy of targets and organs at risk (OARs) can only be addressed by applying additional safety margins, resulting in larger irradiated volumes and possibly higher toxicity.

A promising and innovative technique for margin and in consequence toxicity reduction is online Adaptive Radiotherapy (oART) using daily imaging to create a "plan of the day" aligned to the actual anatomy by means of artificial intelligence (AI) and with the patient on the treatment couch. This approach is especially promising in the pelvic region due to the high anatomic variability, e.g. caused by peristalsis or volume changes of bladder and rectum. Furthermore, the application of oART in the field of thoracic tumors is being evaluated. oART is an already established form of treatment which is used regulary everyday in clinical practice and is not a study-related intervention. A direct comparison of both techniques IGRT vs. oART is missing.

Methods: This prospective and retrospective registry-based trial will include patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART or IGRT. For the primary endpoint and the secondary clinical endpoints, the trial will compare oART versus IGRT, for technical endpoints the trial will compare the real oART scenario with two virtual (hypothetical) control scenarios as follows:

• oART - Applied treatment: AI-based daily treatment plan creation, adapted to daily anatomy

• Virt 1 - Hypothetical dose distribution of initial treatment plan, based on the initial planning CT

• Virt 2 - Hypothetical dose distribution of initial treatment plan, applied to the anatomy of the day as depicted by cone-beam CT at the treatment machine

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 846
• Est. completion date: April 2030
• Est. primary completion date: September 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA

• Patients with pelvic or thoracic tumors with an indication for radiotherapy

• Patient information and declaration of consent

• Patients age = 18 years

EXCLUSION CRITERIA

• Prior radiotherapy in affected site

Related Conditions & MeSH terms

• Pelvic Neoplasms
• Pelvic Tumor
• Thoracic Neoplasms
• Thoracic Tumor

Locations

Country	Name	City	State
Germany	University Medical Center, Departement of Radiation Oncology	Göttingen

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Goettingen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of acute radiotherapy related toxicity	10% reduction in the rate of acute radiotherapy related toxicity (= CTCAE II°, v5.0) using oART	until 12 weeks post RT